These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19464756)

  • 1. A graphic reanalysis of the NINDS Trial.
    Hoffman JR; Schriger DL
    Ann Emerg Med; 2009 Sep; 54(3):329-36, 336.e1-35. PubMed ID: 19464756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
    Hertzberg V; Ingall T; O'Fallon W; Asplund K; Goldfrank L; Louis T; Christianson T
    Clin Trials; 2008; 5(4):308-15. PubMed ID: 18697845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hundred (and one) graphs tell only part of the story.
    Silbergleit R
    Ann Emerg Med; 2009 Sep; 54(3):342-3. PubMed ID: 19695418
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to "A graphic reanalysis of the NINDS Trial".
    Dewey HM; Churilov L; Blacker D; Bladin C; Davis SM; Donnan GA; Gates P; Gerraty RP; Hand P; Levi C; Lindley RI; Markus R; Read S
    Ann Emerg Med; 2010 Feb; 55(2):227-9; author reply 229. PubMed ID: 20116035
    [No Abstract]   [Full Text] [Related]  

  • 5. A regional system of stroke care provides thrombolytic outcomes comparable with the NINDS stroke trial.
    LaMonte MP; Bahouth MN; Magder LS; Alcorta RL; Bass RR; Browne BJ; Floccare DJ; Gaasch WR;
    Ann Emerg Med; 2009 Sep; 54(3):319-27. PubMed ID: 19101059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
    National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
    Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
    Kwiatkowski T; Libman R; Tilley BC; Lewandowski C; Grotta JC; Lyden P; Levine SR; Brott T;
    Ann Emerg Med; 2005 Apr; 45(4):377-84. PubMed ID: 15795715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital.
    Hsu YC; Sung SF; Ong CT; Wu CS; Su YH
    Acta Neurol Taiwan; 2009 Mar; 18(1):14-20. PubMed ID: 19537569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond subgroup analysis: improving the clinical interpretation of treatment effects in stroke research.
    Lu M; Lyden PD; Brott TG; Hamilton S; Broderick JP; Grotta JC
    J Neurosci Methods; 2005 Apr; 143(2):209-16. PubMed ID: 15814153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute stroke management in the elderly.
    Zeevi N; Chhabra J; Silverman IE; Lee NS; McCullough LD
    Cerebrovasc Dis; 2007; 23(4):304-8. PubMed ID: 17199089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravenous tissue plasminogen activator (t-PA) for acute ischemic stroke in a local university hospital].
    Takahashi K; Iijima K; Oguro H; Bokura H; Nagai A; Yamaguchi S; Kobayashi S
    No To Shinkei; 2005 Aug; 57(8):683-8. PubMed ID: 16146212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of tissue plasminogen activator for acute ischemic stroke in a rural Wisconsin hospital.
    Charipar R; Charipar E
    WMJ; 2008 Jul; 107(4):176-80. PubMed ID: 18702433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
    Ingall TJ; O'Fallon WM; Asplund K; Goldfrank LR; Hertzberg VS; Louis TA; Christianson TJ
    Stroke; 2004 Oct; 35(10):2418-24. PubMed ID: 15345796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alteplase treatment for acute stroke 2007: an effective therapeutic option at our disposal].
    Carneado-Ruiz J; Saver JL
    Rev Neurol; 2007 Jul 1-15; 45(1):42-52. PubMed ID: 17620265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prospects of thrombolytic therapy for acute ischemic stroke].
    Nakashima T; Minematsu K
    Brain Nerve; 2009 Sep; 61(9):1003-12. PubMed ID: 19803399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
    Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D
    Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percent change on the National Institutes of Health Stroke Scale: a useful acute stroke outcome measure.
    Bruno A; Saha C; Williams LS
    J Stroke Cerebrovasc Dis; 2009 Jan; 18(1):56-9. PubMed ID: 19110146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue plasminogen activator (tPA) in acute ischaemic stroke: time for collegiate communication and consensus.
    Levi CR; ; ;
    Med J Aust; 2004 Jun; 180(12):634-6. PubMed ID: 15200362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stroking the data: re-analysis of the NINDS trial.
    Magid D; Naviaux N; Wears RL
    Ann Emerg Med; 2005 Apr; 45(4):385-7. PubMed ID: 15795716
    [No Abstract]   [Full Text] [Related]  

  • 20. Prediction of long-term outcome by percent improvement after the first day of thrombolytic treatment in stroke patients.
    Nam HS; Lee KY; Han SW; Kim SH; Lee JY; Ahn SH; Kim DJ; Kim DI; Nam CM; Heo JH
    J Neurol Sci; 2009 Jun; 281(1-2):69-73. PubMed ID: 19304298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.